- Based on an unplanned interim analysis, Geron Corporation (NASDAQ:GERN) announced Monday morning that it will be discontinuing a Phase II study of its developmental drug … Continue Reading
Read nowResearch - BioSante Pharmaceuticals (NASDAQ:BPAX) is giving up gains from Tuesday’s momentary spike and is down 22%, from $1.66 to $1.35. The company reported completion of a … Continue Reading
Read nowQuick Picks - ImmunoCellular Therapeutics (NYSEAMEX:IMUC) is showing big gains on Thursday after the Maxim Group initiated coverage of the company with a Buy rating and a price … Continue Reading
Read nowLong Ideas - Orexigen Therapeutics (NASDAQ:OREX) continues this week’s gains in early trading on Thursday, up roughly 20% to $5.35 since Tuesday. The strength comes from Orexigen’s announcement … Continue Reading
Read nowLong Ideas - After announcing Wednesday morning that it has completed enrollment of its latest Phase 3 Pimavanserin trial, dubbed the -020 study, Acadia Pharmaceuticals (NASDAQ:ACAD) gained 4% … Continue Reading
Read nowQuick Picks - On news of an upcoming conference presentation, Chelsea Therapeutics (NASDAQ:CHTP) is up 16% in afternoon trading at triple its 30-day average volume. Chelsea will present … Continue Reading
Read nowQuick Picks - Shares of BioSante Pharmaceuticals (NASDAQ:BPAX) are up 9% Tuesday on news that the company will be concluding a Phase III safety study of LibiGel, a … Continue Reading
Read now